Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

DPP-4 inhibitors: what may be the clinical differentiators?

Gerich J.

Diabetes Res Clin Pract. 2010 Nov;90(2):131-40. doi: 10.1016/j.diabres.2010.07.006. Epub 2010 Aug 13. Review.

PMID:
20708812
2.

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

Scheen AJ.

Diabetes Metab. 2012 Apr;38(2):89-101. doi: 10.1016/j.diabet.2011.11.001. Epub 2011 Dec 22. Review.

3.

Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.

Bourdel-Marchasson I, Schweizer A, Dejager S.

Hosp Pract (1995). 2011 Feb;39(1):7-21. doi: 10.3810/hp.2011.02.369. Review.

PMID:
21441754
4.

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.

Ahrén B.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):487-98. doi: 10.1016/j.beem.2009.03.003. Review.

PMID:
19748066
5.
6.

Dipeptidyl peptidase-4 inhibitors: 3 years of experience.

Derosa G, Maffioli P.

Diabetes Technol Ther. 2012 Apr;14(4):350-64. doi: 10.1089/dia.2011.0204. Epub 2012 Feb 10. Review.

PMID:
22324384
7.

Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.

Mikhail N.

Expert Opin Investig Drugs. 2008 Jun;17(6):845-53. doi: 10.1517/13543784.17.6.845 . Review.

PMID:
18491986
8.

GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors.

Ahrén B.

Curr Diab Rep. 2007 Oct;7(5):340-7. Review.

PMID:
18173966
9.

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.

Davidson JA, Parente EB, Gross JL.

Arq Bras Endocrinol Metabol. 2008 Aug;52(6):1039-49. Review.

10.

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.

Scheen AJ.

Diabetes Obes Metab. 2010 Aug;12(8):648-58. doi: 10.1111/j.1463-1326.2010.01212.x. Review.

PMID:
20590741
12.

[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].

Kleefstra N, van Hateren KJ, Houweling ST, Verhoeven S, Kooy A, Goudswaard AN, Bilo HJ.

Ned Tijdschr Geneeskd. 2010;154:A886. Review. Dutch.

PMID:
20298625
13.

[Incretin-based therapy for treating patients with type 2 diabetes].

Jermendy G.

Orv Hetil. 2011 Nov 27;152(48):1931-40. doi: 10.1556/OH.2011.29238. Review. Hungarian.

PMID:
22071295
14.

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.

Scheen AJ.

Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Review.

15.

[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].

Gallwitz B.

Pharm Unserer Zeit. 2010 Mar;39(2):114-8. doi: 10.1002/pauz.201000358. Review. German. No abstract available.

PMID:
20196038
16.
17.

An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.

Irons BK, Weis JM, Stapleton MR, Edwards KL.

Curr Diabetes Rev. 2012 May;8(3):169-82. Review.

PMID:
22429011
18.

Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes.

Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch C.

Vasc Health Risk Manag. 2008;4(4):753-68. Review.

19.

DPP4 inhibitors: a new approach in diabetes treatment.

Doupis J, Veves A.

Adv Ther. 2008 Jul;25(7):627-43. doi: 10.1007/s12325-008-0076-1. Review.

PMID:
18641927
20.

Incretin physiology and its role in type 2 diabetes mellitus.

Svec F.

J Am Osteopath Assoc. 2010 Jul;110(7 Suppl 7):eS20-4. Review.

PMID:
20644202

Supplemental Content

Support Center